Beyond the ‘undruggable’: Integrating advanced platforms to conquer membrane protein antibody discovery

In the landscape of modern therapeutics, membrane proteins represent the industry's most valuable and, simultaneously, most frustrating class of targets. While small molecules have successfully targeted these proteins for decades, the development of highly specific, functional monoclonal antibodies (mAbs) has been a profound challenge.

In this article, discover more about the approach built by Creative Biolabs designed to preserve crucial native conformations.